The Social Inequality of Adverse Events
The book’s conclusion reflects on the political and economic context of US Phase I trials. A society characterized by deeply imbricated stigmas ensures that there will always be healthy volunteers willing to enroll in Phase I trials, whether these are the same or new participants who need the financial compensation. Ultimately, attending to the underlying social inequalities animating the Phase I industry is critical to understand what is at stake when healthy volunteers are used in drug development.
Keywords: Phase I trials, healthy volunteers, social inequalities, imbricated stigma, United States, drug development, pharmaceutical industry